SWS Medical(SH:688410) Zheng Quan Ri Bao·2025-08-04 22:27Core Viewpoint - The report details the equity changes of Chongqing Shanwaishan Blood Purification Technology Co., Ltd. due to the share reduction by major shareholders, which does not trigger a change in control or a mandatory tender offer [19][20][22]. Group 1: Shareholder Information - The equity change involves three main parties: Hunan Xiangjiang Liyuan Investment Management Co., Ltd. - Hunan Xiangjiang Dajiankang Venture Capital Partnership (Limited Partnership), Hunan Xiangjiang Liyuan Investment Management Co., Ltd. - Hunan Xiangjiang Liyuan Jiankun Venture Capital Partnership (Limited Partnership), and the original shareholder You Xinnong [19][20]. - The total shares held by these parties decreased from 18,623,449 shares (12.87% of total shares) to 32,131,623 shares (10.00% of total shares) after the reduction [22]. Group 2: Share Reduction Details - The share reduction was executed through centralized bidding transactions, with You Xinnong reducing 1,937,703 shares from June 18, 2024, to September 15, 2024, and the other two parties reducing a total of 7,276,593 shares from June 6, 2025, to August 4, 2025 [8][20][22]. - The total share capital of the company increased from 144,730,259 shares at the time of listing to 321,315,646 shares after two rounds of capital reserve transfers [7][22]. Group 3: Future Plans - The parties involved have no current plans to increase or decrease their holdings beyond the disclosed reduction plan, which allows for a maximum reduction of 12,852,625 shares, representing up to 4.00% of the total share capital [5][20]. - The report confirms that the equity change does not affect the company's controlling shareholder or actual controller [9][19].